Thadeu Costa

Thadeu Costa

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2018 in Molecules
Verified
Journal Article
Open access
PDF file
FRFelipe Rodriguez
Felipe Rodriguez
EIEva Iniguez
Eva Iniguez
GCGuadalupe Pena Contreras
Guadalupe Pena Contreras
HAHaidar Ahmed
Haidar Ahmed
TCThadeu Costa
Thadeu Costa
Rosa MaldonadoRosa Maldonado
Rosa Maldonado
Leishmania major (L. major) is a protozoan parasite that causes cutaneous leishmaniasis. About 12 million people are currently infected with an annual incidence of 1.3 million cases. The purpose of this study was to synthesize a small library of novel thiophene derivatives, and evaluate its parasitic activity, and potential mechanism of action (MOA). We developed a structure–activity relationship (SAR) study of the thiophene molecule 5A. Overall, eight thiophene derivatives of 5A were synthesized and purified by silica gel column chromatography. Of these eight analogs, the molecule 5D showed the highest in vitro activity against Leishmania major promastigotes (EC50 0.09 ± 0.02 µM), with an inhibition of the proliferation of intracellular amastigotes higher than 75% at only 0.63 µM and an excellent selective index. Moreover, the effect of 5D on L. major promastigotes was associated with generation of reactive oxygen species (ROS), and in silico docking studies suggested that 5D may play a role in inhibiting trypanothione reductase. In summary, the combined SAR study and the in vitro evaluation of 5A derivatives allowed the identification of the novel molecule 5D, which exhibited potent in vitro anti-leishmanial activity resulting in ROS production leading to cell death with no significant cytotoxicity towards mammalian cells.

3 April 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
TIThe Brazilian Reproducibility Initiative
The Brazilian Reproducibility Initiative
OAOlavo Bohrer Amaral
Olavo Bohrer Amaral
CCClarissa França Dias Carneiro
Clarissa França Dias Carneiro
KNKleber Neves
Kleber Neves
ASAna Paula Wasilewska Sampaio
Ana Paula Wasilewska Sampaio
WAWanessa Fernanda Altei
Wanessa Fernanda Altei
Concerns over the replicability and reproducibility of published research have grown in many research fields, but empirical data to inform policies are still scarce. Biomedical research in Brazil expanded rapidly over the last three decades, with no systematic assessment of the replicability of its findings. With this in mind, we set up the Brazilian Reproducibility Initiative, a multicenter replication of published experiments from Brazilian science using three common experimental methods: the MTT assay, the reverse transcription polymerase chain reaction (RT-PCR) and the elevated plus maze (EPM). A total of 56 laboratories performed 143 replications of 56 experiments; of these, 90 replications of 45 experiments were considered valid by an independent committee. Replication rates for these experiments varied between 20 and 44% according to five predefined criteria. In median terms, ratios between group means were 58% lower in replications than in original experiments, while coefficients of variation were 82% higher. Effect size decrease was smaller for MTT experiments, original results with less variability and those considered more challenging to replicate, while t values for replications were positively correlated with researcher predictions about replicability, and negatively correlated with the rate of publications by the original article’s last author. Deviations from preregistered protocols were very common in replications, most frequently due to reasons inherent to the experimental model or related to infrastructure and logistics. Our results highlight factors that limit the replicability of results published by researchers in Brazil and suggest ways by which this scenario can be improved.

5 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
TCThadeu Costa
Thadeu Costa
TPTatiana Almeida Pádua
Tatiana Almeida Pádua
JPJonathas Xavier Pereira
Jonathas Xavier Pereira
VRVinicius Gonçalves Rodrigues
Vinicius Gonçalves Rodrigues
LSLeonardo Noboru Seito
Leonardo Noboru Seito
CPCarmen Penido
Carmen Penido
Background: Glioblastoma is the most invasive and malignant brain tumor, for which no effective treatment is currently available. Heat shock protein 90 (HSP90) is a potential target for the treatment of different types of cancer. Herein, we investigated the effect of gedunin, an HSP90 inhibitor, in murine GL261 glioblastoma in vitro and in vivo models. Methods: Gedunin effects were assessed by in vitro cell viability assay (MTT), apoptosis (PI/Annexin staining), proliferation (CFSE), invasion (transmigration, scratch assay and zymography), protein detection (western blot) and in vivo orthotopic glioblastoma model (brain computed tomography and histology). Results: Gedunin treatment decreased GL261 cell proliferation and triggered apoptosis in a concentration-dependent manner. Gedunin also reduced GL261 cell migration and metalloproteinase-2 activity, suggesting that it impairs glioblastoma cell invasion. Despite the reduction of total protein content in gedunin-treated cells, the phosphorylation of STAT3 and ERK1/2 pathways was enhanced within 24 h. In situ treatment with gedunin did not significantly reduce tumor volume. Still, it reduced the tumor central area and the presence of vascular structures in xenograft glioblastoma in C57BL/6 mice, a clinical feature associated with morbidity and mortality. Conclusion: Gedunin inhibits murine glioblastoma cell growth and proliferation by inducing apoptosis. Graphical

26 February 2026 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
EREduardo Ricci Ricci-Júnior
Eduardo Ricci Ricci-Júnior
LMLuana Santos Monteiro
Luana Santos Monteiro
ALAna Carolina Souza de Lima
Ana Carolina Souza de Lima
ATAnna Lecticia Martinez Martinez Toledo
Anna Lecticia Martinez Martinez Toledo
MARCOS DIASMARCOS DIAS
MARCOS DIAS
MMMariana Monteiro
Mariana Monteiro
Background: Chronic and complex wounds remain a significant clinical challenge, requiring biomaterials that can provide structural support and bioactive signaling. Pentaclethra macroloba (Pracaxi) oil is recognized for its regenerative properties; its integration into advanced delivery systems, such as electrospun nanofibers, which offer high surface area and mimic extracellular matrix, remains unexplored. This work aimed to develop and characterize poly(lactic acid) (PLA) nanofibers loaded with Pracaxi oil (OP) as an innovative bioactive dressing for wound healing. Methods: The chemical profile of OP was determined by gas chromatography-mass spectrometry (GC–MS). PLA/OP nanofibers (1%–20% w/w) were produced via electrospinning process and characterized by scanning electron microscopy (SEM), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FTIR), and thermal analysis (DSC/TGA). Biological performance was evaluated using human keratinocyte (HaCaT) viability (MTT assay) and cell migration (scratch assay). Results: CG-MS identified 11 fatty acids (98.95%), with oleic acid (50.93%) and behenic acid as the primary bioactive component. OP incorporation influenced fiber diameter and induced the formation of beads, which reduced the mat porosity. The oil acted as a plasticizer, slightly decreasing the glass transition temperature (Tg) and thermal stability, while the amorphous structure of PLA was preserved. Nanofibers containing up to 15% w/w of OP demonstrated excellent biocompatibility, with cell viability exceeding 100%. The 15% w/w of OP formulation was identified as the optimal system, significantly accelerating keratinocyte migration compared to pure PLA and control groups ( p < 0.01). Conclusions: This study successfully integrated OP into PLA nanofibers for the first time. The resulting membrane combines the structural advantages of nanofibers with the therapeutic benefits of PO. Specifically, the 15% w/w formulation is a promising biomimetic scaffold for wound healing. Future in vivo studies are suggested to confirm these findings. Graphical

29 July 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
TPTatiana Almeida Pádua
Tatiana Almeida Pádua
MPMariana Xavier Vasconcelos Passos
Mariana Xavier Vasconcelos Passos
EMEllen Damásio Mascarenhas
Ellen Damásio Mascarenhas
GSGabriel Parreiras Estolano Silveira
Gabriel Parreiras Estolano Silveira
DPDouglas Pereira Pinto
Douglas Pereira Pinto
TGThiago Frances Guimarães
Thiago Frances Guimarães
Malaria remains a major global health burden, especially in children under the age of five. Pediatric treatment often requires tablet fragmentation for its dose adjustment according to body weight, which intensifies bitterness and may reduce treatment adherence. Complexation of bitter-tasting drugs with ion-exchange resins for taste masking is a promising strategy to improve palatability. Here, we evaluated whether a chloroquine–resin complex (CLQ-R) preserves the pharmacokinetic profile and antimalarial efficacy of chloroquine diphosphate (CLQ) while masking its bitter taste. CLQ-R was prepared at a 1:1 (w/w) drug-to-resin ratio using polacrilin potassium (Amberlite IRP88). The in vitro antimalarial activity of CLQ-R was assessed using Plasmodium falciparum 3D7 strain, and the parasite proliferation was determined by SYBR Green DNA-staining. CLQ plasma concentrations and mice biochemical parameters were evaluated following oral administration of CLQ or CLQ-R. The in vivo antimalarial activity was evaluated in P. berghei ANKA–infected C57BL/6 mice using the four-day suppressive and recrudescence tests, with parasitemia assessed by flow cytometry. Taste perception was determined by 48-hour two-bottle preference test. CLQ-R displayed similar plasma concentration and biochemical profiles to CLQ. CLQ-R was able to maintain a strong in vitro antimalarial activity with IC50 of 30 nM with minimal hemolytic activity and reduced in vivo parasitemia by >95%. Notably, mice exhibited a 15.5% higher preference for CLQ-R, indicating improved palatability. These findings demonstrate that CLQ-R preserves CLQ pharmacological activity while masking its bitter taste, supporting its potential as a pediatric-friendly antimalarial formulation.